Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

April 1, 2015 updated by: Indiana University
The goal in these studies will be to assess the relative levels of the Stat4 alpha and Stat4 beta isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, celiac disease or from control patients. We hypothesize that the beta to alpha ratio will be higher in patients with active disease and that there will be a correlation between the ratio and the severity of disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

51

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University-Riley Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
  • Clinical diagnosis within the previous 21 days
  • Above age 7 and younger than age 18
  • Signed informed consent statement and assent statement.
  • Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
  • Clinical diagnosis within the previous 21 days
  • Above age 7 and younger than age 18
  • Signed informed consent statement and assent statement.
  • Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
  • Clinical diagnosis of Crohn's Disease
  • Above age 7 and younger that age 18
  • Signed informed consent statement and assent statement.
  • Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
  • Clinical diagnosis of Ulcerative Colitis
  • Above age 7 and younger than age 18
  • Signed informed consent statement and assent statement.
  • Healthy Controls (10 Subjects):
  • Above age 7 and younger than age 18
  • otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
  • controls will be gender and age (± 2 years) matched to the patient groups described above
  • Signed informed consent statement and assent statement

Exclusion Criteria:

  • unwilling to give consent for this study.
  • child with prior prescription and administration of Infliximab

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control
Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
measuring inflammatory markers and comparing to controls.
Other: IBD and infliximab
Subjects who have IBD and will be receiving infliximab for the first time.
measuring inflammatory markers and comparing to controls.
Other: Newly Diagnosed IBD
Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
measuring inflammatory markers and comparing to controls.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
This study hopes to assess the relative levels of the Stat4a and Stat4β isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, or from control patients.
Time Frame: Total duration of treatment will be 20-24 weeks (Arm A and Arm B) or 50-54 weeks (Arm C/ Arm D).
Total duration of treatment will be 20-24 weeks (Arm A and Arm B) or 50-54 weeks (Arm C/ Arm D).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Steven J Steiner, MD, Indiana University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2007

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

December 21, 2007

First Submitted That Met QC Criteria

December 21, 2007

First Posted (Estimate)

January 4, 2008

Study Record Updates

Last Update Posted (Estimate)

April 3, 2015

Last Update Submitted That Met QC Criteria

April 1, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • 0707-69
  • IRB # 0707-69

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.